We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > tisagenlecleucel

News List

Scottish Medicines Consortium tisagenlecleucel (Kymriah) firstwordpharma
March 12, 2019
For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Novartis’ Kymriah shows ‘strong efficacy’, ‘durable response’ in new analysis pharmatimes
December 04, 2018
Novartis has released longer-term analyses of data from the ELIANA and JULIET trials showing that its CAR-T cell therapy Kymriah demonstrated “strong efficacy” and “durable responses” in certain blood cancer patients.
CAR-T cell update: Therapy improves outcomes for patients with B-cell lymphoma worldpharmanews
December 04, 2018
In their phase-2 study of tisagenlecleucel (marketed as KYMRIAH®), to be published on-line Dec. 1, 2018 in the New England Journal of Medicine, an international team of researchers evaluated 93 patients with relapsed or refractory diffuse large B-cell lym